{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:50:30Z","timestamp":1791503430086,"version":"4.3.4"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.yrtph.2026.106272","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:35:20Z","timestamp":1791318920000},"page":"106272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Beyond kratom: Concentrated 7-hydroxymitragynine and mitragynine pseudoindoxyl products, an MME potency assessment"],"prefix":"10.1016","volume":"173","author":[{"given":"Jonathan","family":"Heywood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Farnham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Steimel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Riordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.yrtph.2026.106272_bib3","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1097\/j.pain.0000000000003529","article-title":"Standardizing research methods for opioid dose comparison: the NIH HEAL morphine milligram equivalent calculator","volume":"166","author":"Adams","year":"2025","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.yrtph.2026.106272_bib4","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1080\/13880209.2025.2590311","article-title":"From kratom to 7-Hydroxymitragynine: evolution of a natural remedy into a public-health threat","volume":"63","author":"Alsbrook","year":"2025","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.yrtph.2026.106272_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.phytochem.2026.114871","article-title":"Quantitative analysis of 7-hydroxymitragynine in commercial kratom products and its stability under chemical and physiological conditions","volume":"247","author":"Avula","year":"2026","journal-title":"Phytochemistry"},{"key":"10.1016\/j.yrtph.2026.106272_bib7","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1124\/dmd.121.000640","article-title":"The lack of contribution of 7-Hydroxymitragynine to the antinociceptive effects of mitragynine in mice: a pharmacokinetic and pharmacodynamic study","volume":"50","author":"Berthold","year":"2022","journal-title":"Drug Metabol. Dispos."},{"issue":"5","key":"10.1016\/j.yrtph.2026.106272_bib8","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/MLR.0000000000000505","article-title":"A detailed exploration into the Association of Prescribed Opioid dosage and overdose deaths among patients with chronic pain","volume":"54","author":"Bohnert","year":"2016","journal-title":"Med. Care"},{"key":"10.1016\/j.yrtph.2026.106272_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2025.1479863","article-title":"Case report: cannabis and kratom-induced self-amputation of ears and penis","volume":"16","author":"Broul","year":"2025","journal-title":"Front. Psychiatr."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106272_bib11","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/jaoacint\/qsaf094","article-title":"Elevated 7-Hydroxymitragynine levels found in products misbranded as kratom","volume":"109","author":"Brown","year":"2026","journal-title":"J. AOAC Int."},{"key":"10.1016\/j.yrtph.2026.106272_bib10","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jep.2017.03.020","article-title":"A botanical, phytochemical and ethnomedicinal review of the genus Mitragyna korth: implications for products sold as kratom","volume":"202","author":"Brown","year":"2017","journal-title":"J. Ethnopharmacol."},{"issue":"22","key":"10.1016\/j.yrtph.2026.106272_bib12","doi-asserted-by":"crossref","first-page":"16553","DOI":"10.1021\/acs.jmedchem.1c01111","article-title":"Oxidative metabolism as a modulator of Kratom's biological actions","volume":"64","author":"Chakraborty","year":"2021","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.yrtph.2026.106272_bib13","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1021\/acs.jnatprod.0c01055","article-title":"Exploring the chemistry of alkaloids from Malaysian Mitragyna speciosa (Kratom) and the role of oxindoles on human opioid receptors","volume":"84","author":"Chear","year":"2021","journal-title":"J. Nat. Prod."},{"issue":"8","key":"10.1016\/j.yrtph.2026.106272_bib14","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/AJP.0000000000000948","article-title":"Inches, centimeters, and yards: overlooked definition choices inhibit interpretation of morphine equivalence","volume":"37","author":"Dasgupta","year":"2021","journal-title":"Clin. J. Pain"},{"key":"10.1016\/j.yrtph.2026.106272_bib15","first-page":"40917","article-title":"Schedules of controlled substance: temporary placement of 7-Hydroxymitragynine above a specified threshold in schedule I","volume":"91","year":"2026"},{"key":"10.1016\/j.yrtph.2026.106272_bib16","first-page":"40909","article-title":"Schedules of controlled substances: temporary placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in schedule I","volume":"91","year":"2026"},{"issue":"RR-1","key":"10.1016\/j.yrtph.2026.106272_bib17","first-page":"1","article-title":"CDC Guideline for prescribing opioids for chronic pain \u2014 united States, 2016","volume":"65","author":"Dowell","year":"2016","journal-title":"MMWR Recomm. Rep. (Morb. Mortal. Wkly. Rep.)"},{"issue":"RR-3","key":"10.1016\/j.yrtph.2026.106272_bib18","first-page":"1","article-title":"CDC Clinical Practice Guideline for Prescribing Opioids for Pain \u2014 united States, 2022","volume":"71","author":"Dowell","year":"2022","journal-title":"MMWR Recomm. Rep. (Morb. Mortal. Wkly. Rep.)"},{"key":"10.1016\/j.yrtph.2026.106272_bib19","series-title":"Kratom: History, Science and Therapeutic Potential","article-title":"Regulation and policy regarding kratom-derived dietary supplements and direct-to-consumer sales","author":"Durkin","year":"2025"},{"issue":"7","key":"10.1016\/j.yrtph.2026.106272_bib20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/AJP.0000000000000021","article-title":"The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic non-cancer pain: the role of opioid prescription","volume":"30","author":"Edlund","year":"2014","journal-title":"Clin. J. Pain"},{"issue":"2","key":"10.1016\/j.yrtph.2026.106272_bib21","first-page":"9704","article-title":"Kratom (Mitragyna speciosa Korth) for a new medicinal: a review of pharmacological and compound analysis","volume":"11","author":"Firmansyah","year":"2021","journal-title":"Biointerface Res. Appl. Chem."},{"key":"10.1016\/j.yrtph.2026.106272_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.forc.2023.100474","article-title":"Analysis of heavy metals content in commercially available kratom products in Richmond, Virginia","volume":"33","author":"Fleming","year":"2023","journal-title":"Forensic Chem."},{"key":"10.1016\/j.yrtph.2026.106272_bib23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.forsciint.2019.04.009","article-title":"A validated method for the quantification of mitragynine in sixteen commercially available Kratom (Mitragyna speciosa) products","volume":"299","author":"Fowble","year":"2019","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.yrtph.2026.106272_bib24","series-title":"The Toxic NOSE (Novel Opioid and Stimulant Exposure), Report #18 from Toxic's Rapid Response Program for Emerging Drugs of Abuse: American College of Medical Toxicology (ACMT)","first-page":"1","article-title":"7-Hydroxymitragynine: a high-risk supplement marketed as kratom","author":"Gaetani","year":"2025"},{"key":"10.1016\/j.yrtph.2026.106272_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.107849","article-title":"Kratom (Mitragyna speciosa): user demographics, use patterns, and implications for the opioid epidemic","volume":"208","author":"Garcia-Romeu","year":"2020","journal-title":"Drug Alcohol Depend."},{"issue":"12","key":"10.1016\/j.yrtph.2026.106272_bib26","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1002\/dta.3952","article-title":"From kratom to semi-synthetic opioids: the rise and risks of MGM-15","volume":"17","author":"Gour","year":"2025","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.yrtph.2026.106272_bib27","first-page":"1","article-title":"Prevalence and use patterns of kratom (Mitragyna speciosa Korth.) in a US nationally representative sample","author":"Grundmann","year":"2025","journal-title":"J. Psychoact. Drugs"},{"issue":"3","key":"10.1016\/j.yrtph.2026.106272_bib28","doi-asserted-by":"crossref","DOI":"10.1111\/adb.70126","article-title":"The buprenorphine paradox: how buprenorphine triggers and resolves opioid withdrawal","volume":"31","author":"Haghdoost","year":"2026","journal-title":"Addict. Biol."},{"key":"10.1016\/j.yrtph.2026.106272_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1403140","article-title":"Kratom safety and toxicology in the public health context: research needs to better inform regulation","volume":"15","author":"Henningfield","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106272_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2024.114913","article-title":"Beneficial and adverse health effects of kratom (Mitragyna speciosa): a critical review of the literature","volume":"192","author":"Heywood","year":"2024","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.yrtph.2026.106272_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2025.112701","article-title":"De facto opioids: characterization of novel 7-hydroxymitragynine and mitragynine pseudoindoxyl product marketing","volume":"272","author":"Hill","year":"2025","journal-title":"Drug Alcohol Depend."},{"issue":"14","key":"10.1016\/j.yrtph.2026.106272_bib31","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1111\/bph.15832","article-title":"The respiratory depressant effects of mitragynine are limited by its conversion to 7-OH mitragynine","volume":"179","author":"Hill","year":"2022","journal-title":"Br. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.yrtph.2026.106272_bib33","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1007\/s00213-019-05247-7","article-title":"The effects of mitragynine and morphine on schedule-controlled responding and antinociception in rats","volume":"236","author":"Hiranita","year":"2019","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.yrtph.2026.106272_bib34","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1055\/s-2005-837822","article-title":"Indole alkaloids of a Thai medicinal herb, Mitragyna speciosa, that has opioid agonistic effect in guinea-pig ileum","volume":"71","author":"Horie","year":"2005","journal-title":"Planta Med."},{"issue":"984","key":"10.1016\/j.yrtph.2026.106272_bib35","article-title":"Human mitragynine and 7-Hydroxymitragynine pharmacokinetics after single and multiple daily doses of oral encapsulated dried kratom leaf powder","volume":"29","author":"Huestis","year":"2024","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.yrtph.2026.106272_bib37","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1021\/acsptsci.0c00075","article-title":"Metabolism of a Kratom Alkaloid Metabolite in human plasma increases its opioid potency and efficacy","volume":"3","author":"Kamble","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"3","key":"10.1016\/j.yrtph.2026.106272_bib38","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1124\/jpet.122.001525","article-title":"Pharmacokinetic and pharmacodynamic consequences of cytochrome P450 3A inhibition on mitragynine metabolism in rats","volume":"385","author":"Kamble","year":"2023","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"11","key":"10.1016\/j.yrtph.2026.106272_bib36","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1080\/00498254.2018.1552819","article-title":"Metabolite profiling and identification of enzymes responsible for the metabolism of mitragynine, the major alkaloid of Mitragyna speciosa (kratom)","volume":"49","author":"Kamble","year":"2019","journal-title":"Xenobiotica"},{"key":"10.1016\/j.yrtph.2026.106272_bib44","series-title":"House Bill 2365: an Act Concerning Controlled Substances; Adding and Removing Certain Substances in Schedule I, III and IV of the Uniform Controlled Substances Act","year":"2026"},{"key":"10.1016\/j.yrtph.2026.106272_bib39","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11419-009-0070-5","article-title":"Simultaneous analysis of mitragynine, 7-hydroxymitragynine, and other alkaloids in the psychotropic plant \u201ckratom\u201d (Mitragyna speciosa) by LC-ESI-MS","volume":"27","author":"Kikura-Hanajiri","year":"2009","journal-title":"Forensic Toxicol."},{"issue":"21","key":"10.1016\/j.yrtph.2026.106272_bib41","doi-asserted-by":"crossref","first-page":"6754","DOI":"10.1021\/jacs.6b00360","article-title":"Synthetic and receptor signaling explorations of the Mitragyna alkaloids: mitragynine as an atypical molecular framework for opioid receptor modulators","volume":"138","author":"Kruegel","year":"2016","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.yrtph.2026.106272_bib40","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.neuropharm.2017.08.026","article-title":"The medicinal chemistry and neuropharmacology of kratom: a preliminary discussion of a promising medicinal plant and analysis of its potential for abuse","volume":"134","author":"Kruegel","year":"2018","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.yrtph.2026.106272_bib42","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1021\/acscentsci.9b00141","article-title":"7-Hydroxymitragynine is an active metabolite of mitragynine and a key mediator of its analgesic effects","volume":"5","author":"Kruegel","year":"2019","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.yrtph.2026.106272_bib43","series-title":"Kratom Summary of State Laws: Legislative Analysis and Public Policy Association (LAPPA). January 2026","year":"2026"},{"key":"10.1016\/j.yrtph.2026.106272_bib45","article-title":"Management of acute withdrawal from 7-hydroxymitragynine after high-dose chronic use: a case report","volume":"66","author":"Lybik","year":"2026","journal-title":"J. Am. Pharmaceut. Assoc."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106272_bib46","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/19253621231160417","article-title":"Postmortem mitragynine distribution in a single drug fatality case","volume":"13","author":"Mata","year":"2023","journal-title":"Academic Forensic Pathology"},{"issue":"1\u20133","key":"10.1016\/j.yrtph.2026.106272_bib48","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejphar.2006.08.013","article-title":"Involvement of Mu-Opioid receptors in antinociception and inhibition of gastrointestinal transit induced by 7-Hydroxymitragynine, isolated from Thai herbal medicine Mitragyna speciosa","volume":"549","author":"Matsumoto","year":"2006","journal-title":"Eur. J. Pharmacol."},{"issue":"17","key":"10.1016\/j.yrtph.2026.106272_bib47","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/j.lfs.2003.09.054","article-title":"Antinociceptive effect of 7-Hydroxymitragynine in mice: discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa","volume":"74","author":"Matsumoto","year":"2004","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.yrtph.2026.106272_bib49","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1124\/jpet.113.208108","article-title":"Orally active opioid m\/d dual agonist MGM-16, a derivative of the indole alkaloid mitragynine, exhibits potent antiallodynic effect on neuropathic pain in mices","volume":"348","author":"Matsumoto","year":"2014","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"2","key":"10.1016\/j.yrtph.2026.106272_bib50","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/17512433.2024.2305798","article-title":"An update on the clinical pharmacology of kratom: uses, abuse potential, and future considerations","volume":"17","author":"McCurdy","year":"2024","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.yrtph.2026.106272_bib51","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1021\/acsptsci.3c00335","article-title":"Effects of itraconazole on pharmacokinetics of mitragynine and 7-Hydroxymitragynine in healthy volunteers","volume":"7","author":"Mongar","year":"2024","journal-title":"Pharmacol. Transl. Sci."},{"key":"10.1016\/j.yrtph.2026.106272_bib52","doi-asserted-by":"crossref","DOI":"10.1097\/ADM.0000000000001637","article-title":"Prevalence and correlates of past-year kratom use among US adults: findings from the 2021-2023 National Survey on drug use and health","author":"Mun","year":"2026","journal-title":"J. Addiction Med."},{"issue":"6","key":"10.1016\/j.yrtph.2026.106272_bib53","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/pds.3945","article-title":"A synthesis of Oral Morphine Equivalents (OME) for opioid utilisation studies","volume":"25","author":"Nielsen","year":"2016","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.yrtph.2026.106272_bib54","article-title":"NIH research clears way for study of experimental treatment for opioid use disorder: IND in effect for human safety study of mitragynine, a kratom isolate","year":"2026","journal-title":"National Institutes of Health (NIH)"},{"key":"10.1016\/j.yrtph.2026.106272_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176863","article-title":"The Mitragyna speciosa (Kratom) Alkaloid mitragynine: analysis of adrenergic \u03b12 receptor activity in vitro and in vivo","volume":"980","author":"Obeng","year":"2024","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.yrtph.2026.106272_bib55","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1124\/jpet.120.000189","article-title":"Pharmacological comparison of mitragynine and 7-Hydroxymitragynine: in vitro affinity and efficacy for \u03bc-Opioid receptor and opioid-like behavioral effects in rats","volume":"376","author":"Obeng","year":"2021","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.yrtph.2026.106272_bib1","series-title":"Morphia Limited Edition 7-Hydroxy Tablets 3000mg","year":"2026"},{"issue":"10","key":"10.1016\/j.yrtph.2026.106272_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/ph16101397","article-title":"An examination of the complex pharmacological properties of the non-selective opioid modulator buprenorphine","volume":"16","author":"Pande","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"6","key":"10.1016\/j.yrtph.2026.106272_bib58","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1055\/s-2006-959578","article-title":"A New Indole Alkaloid, 7 alpha-Hydroxy-7H-mitragynine, from Mitragyna speciosa in Thailand","volume":"60","author":"Ponglux","year":"1994","journal-title":"Planta Med."},{"issue":"2","key":"10.1016\/j.yrtph.2026.106272_bib59","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40429-023-00478-3","article-title":"Clinical implications of kratom (Mitragyna speciosa) use: a literature review","volume":"10","author":"Prevete","year":"2023","journal-title":"Current Addiction Reports"},{"issue":"6","key":"10.1016\/j.yrtph.2026.106272_bib60","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00213-024-06734-2","article-title":"An exploratory Study of the safety profile and neurocognitive function after single doses of mitragynine in humans","volume":"242","author":"Prevete","year":"2025","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.yrtph.2026.106272_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijerph17155512","article-title":"Evaluation of the mitragynine content, levels of toxic metals and the presence of microbes in Kratom products purchased in the Western suburbs of Chicago","volume":"17","author":"Prozialeck","year":"2020","journal-title":"Int. J. Environ. Res. Publ. Health"},{"issue":"1","key":"10.1016\/j.yrtph.2026.106272_bib62","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/15563650.2025.2565428","article-title":"Cardio-Pulmonary arrest in a patient revived with naloxone following reported use of 7-Hydroxymitragynine","volume":"64","author":"Pullman","year":"2026","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.yrtph.2026.106272_bib64","series-title":"Pseudoindoxyl Tablets","year":"2026"},{"key":"10.1016\/j.yrtph.2026.106272_bib65","doi-asserted-by":"crossref","DOI":"10.1097\/ADM.0000000000001603","article-title":"Substance use disorder following consumption of a novel synthetic 7-Hydroxymitragynine product","author":"Reif","year":"2025","journal-title":"J. Addiction Med."},{"issue":"4","key":"10.1016\/j.yrtph.2026.106272_bib66","first-page":"386","article-title":"A pilot, Dose-Finding, pharmacodynamic and pharmacokinetic Study of orally administered botanical kratom","volume":"46","author":"Reissig","year":"2026","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.yrtph.2026.106272_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2024.111329","article-title":"Kratom addiction per DSM-5 SUD criteria, and kratom physical dependence: insights from dosing amount versus frequency","volume":"260","author":"Rogers","year":"2024","journal-title":"Drug Alcohol Depend."},{"issue":"3","key":"10.1016\/j.yrtph.2026.106272_bib68","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jep.2013.02.008","article-title":"Subchronic exposure to mitragynine, the principal alkaloid of Mitragyna speciosa, in rats","volume":"146","author":"Sabetghadam","year":"2013","journal-title":"J. Ethnopharmacol."},{"issue":"2","key":"10.1016\/j.yrtph.2026.106272_bib69","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.bja.2023.10.041","article-title":"Clarifying intrinsic efficacy, partial agonism, and full agonism: the case of buprenorphine","volume":"132","author":"Samways","year":"2024","journal-title":"Br. J. Anaesth."},{"issue":"4","key":"10.1016\/j.yrtph.2026.106272_bib70","doi-asserted-by":"crossref","DOI":"10.3390\/plants12040949","article-title":"Seasonal and geographic variation in Alkaloid content of kratom (Mitragyna speciosa (Korth.) Havil.) from Thailand","volume":"12","author":"Sengnon","year":"2023","journal-title":"Plants"},{"issue":"8","key":"10.1016\/j.yrtph.2026.106272_bib71","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1002\/dta.2604","article-title":"Simultaneous quantification of ten key Kratom alkaloids in Mitragyna speciosa leaf extracts and commercial products by ultra-performance liquid chromatography\u2013tandem mass spectrometry","volume":"11","author":"Sharma","year":"2019","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.yrtph.2026.106272_bib72","article-title":"7-Hydroxymitragynine and nicotine pouch withdrawal syndrome: a case report","volume":"17","author":"Sharma","year":"2025","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.yrtph.2026.106272_bib73","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1021\/jasms.6c00088","article-title":"Avoiding false identification of 7-Hydroxymitragynine in kratom products using a Multicriteria LC-MS confirmation","volume":"37","author":"Sheehan","year":"2026","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.yrtph.2026.106272_bib75","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jep.2017.12.017","article-title":"Evaluating the hematological and clinical-chemistry parameters of kratom (Mitragyna speciosa) users in Malaysia","volume":"214","author":"Singh","year":"2018","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.yrtph.2026.106272_bib74","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.drugalcdep.2014.03.017","article-title":"Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users","volume":"139","author":"Singh","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.yrtph.2026.106272_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1620601","article-title":"The acute adverse health effects of kratom: an evaluation of case reports","volume":"16","author":"Smallets","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106272_bib78","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.53401","article-title":"Ecological momentary assessment of self-reported kratom use, effects, and motivations among US adults","volume":"7","author":"Smith","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.yrtph.2026.106272_bib77","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1021\/acs.chemrestox.8b00218","article-title":"Lateral flow assessment and unanticipated toxicity of kratom","volume":"32","author":"Smith","year":"2019","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.yrtph.2026.106272_bib79","article-title":"How much kratom to take: kratom serving size guide","author":"Speciosa","year":"2026","journal-title":"Super Speciosa"},{"issue":"3","key":"10.1016\/j.yrtph.2026.106272_bib80","article-title":"Severe early-onset withdrawal following intentional use of mitragynine Pseudoindoxyl: a case report and emerging clinical considerations","volume":"18","author":"Stanciu","year":"2026","journal-title":"Cureus"},{"issue":"9","key":"10.1016\/j.yrtph.2026.106272_bib81","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1021\/jm010576e","article-title":"Studies on the synthesis and opioid agonistic activities of mitragynine-related indole alkaloids: discovery of opioid agonists structurally different from other opioid ligands","volume":"45","author":"Takayama","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.yrtph.2026.106272_bib5","series-title":"House Bill 1649: an Act to Amend Tennessee Code Annotated","year":"2026"},{"key":"10.1016\/j.yrtph.2026.106272_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-76119-w","article-title":"Chemical composition and biological effects of kratom (Mitragyna speciosa): in vitro studies with implications for efficacy and drug interactions","volume":"10","author":"Todd","year":"2020","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.yrtph.2026.106272_bib83","doi-asserted-by":"crossref","first-page":"139","DOI":"10.15585\/mmwr.mm7511a1","article-title":"Increases in kratom-related reports to poison centers \u2014 national poison data System, United States, 2015\u20132025","volume":"75","author":"Towers","year":"2026","journal-title":"MMWR Morbidity and Mortality Weekly Report"},{"key":"10.1016\/j.yrtph.2026.106272_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1632835","article-title":"Reported associations between kratom and seizures: a systematic review","volume":"16","author":"Turla","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106272_bib85","series-title":"News: August 2025 \u2013 Emergence of Potent kratom-related Products Containing 7-hydroxymitragynine and\/or Mitragynine Pseudoindoxyl","year":"2025"},{"key":"10.1016\/j.yrtph.2026.106272_bib86","article-title":"FDA Adverse Event Monitoring System (AEMS) Public Dashboard [formerly FDA Adverse Event Reporting System (FAERS)]","year":"2026","journal-title":"United States Food and Drug Administration (FDA)"},{"key":"10.1016\/j.yrtph.2026.106272_bib87","series-title":"United States Food and Drug Administration (FDA)","article-title":"FDA Adverse Event Monitoring System (AEMS): 7-Hydroxymitragynine adverse event reports","year":"2026"},{"key":"10.1016\/j.yrtph.2026.106272_bib88","series-title":"United States Food and Drug Administration (FDA)","article-title":"FDA Adverse Event Monitoring System (AEMS): mitragynine adverse event reports","year":"2026"},{"key":"10.1016\/j.yrtph.2026.106272_bib89","series-title":"United States Food and Drug Administration (FDA)","article-title":"FDA Adverse Event Monitoring System (AEMS): mitragynine Pseudoindoxyl adverse event reports","year":"2026"},{"key":"10.1016\/j.yrtph.2026.106272_bib90","series-title":"United States Food and Drug Administration (FDA)","article-title":"Human Foods Complaint System (HFCS)","year":"2026"},{"issue":"18","key":"10.1016\/j.yrtph.2026.106272_bib91","doi-asserted-by":"crossref","first-page":"8381","DOI":"10.1021\/acs.jmedchem.6b00748","article-title":"Mitragynine\/Corynantheidine pseudoindoxyls as opioid analgesics with Mu agonism and Delta antagonism, which do not recruit \u03b2-Arrestin-2","volume":"59","author":"V\u00e1radi","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.yrtph.2026.106272_bib92","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.yrtph.2010.12.007","article-title":"Uniform assessment and ranking of Mu receptor binding constants for selected opioid drugs","volume":"59","author":"Volpe","year":"2011","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"6","key":"10.1016\/j.yrtph.2026.106272_bib93","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/AJP.0b013e318169d03b","article-title":"De Facto Long-term Opioid Therapy for Non-Cancer Pain","volume":"24","author":"Von Korff","year":"2008","journal-title":"Clin. J. Pain"},{"issue":"2","key":"10.1016\/j.yrtph.2026.106272_bib94","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/1925362118782076","article-title":"Fatal mitragynine-associated toxicity in Canada: a case report and review of the literature","volume":"8","author":"Wang","year":"2018","journal-title":"Academic Forensic Pathology"},{"issue":"1","key":"10.1016\/j.yrtph.2026.106272_bib95","doi-asserted-by":"crossref","DOI":"10.3390\/psychoactives5010007","article-title":"Mitragynine pseudoindoxyl withdrawal treated with macro-dosed buprenorphine induction: a case report and review of the literature","volume":"5","author":"Warrick-Stone","year":"2026","journal-title":"Psychoactives"},{"key":"10.1016\/j.yrtph.2026.106272_bib96","series-title":"Re: Clarification of Opioid Prescribing Rules","year":"2019"},{"issue":"12","key":"10.1016\/j.yrtph.2026.106272_bib97","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0024-3205(97)00023-4","article-title":"Inhibitory effect of mitragynine, an alkaloid with analgesic effect from Thai medicinal plant Mitragyna speciosa, on electrically stimulated contraction of isolated guinea-pig ileum through the opioid receptor","volume":"60","author":"Watanabe","year":"1997","journal-title":"Life Sci."},{"key":"10.1016\/j.yrtph.2026.106272_bib98","article-title":"A case of 7-OH mitragynine use requiring inpatient medically managed withdrawal","author":"Wightman","year":"2025","journal-title":"J. Addiction Med."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106272_bib99","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0306-3623(98)00265-1","article-title":"Opioid receptor agonistic characteristics of mitragynine Pseudoindoxyl in comparison with mitragynine derived from Thai medicinal plant Mitragyna speciosa","volume":"33","author":"Yamamoto","year":"1999","journal-title":"Gen. Pharmacol."},{"issue":"11","key":"10.1016\/j.yrtph.2026.106272_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpet.2025.103720","article-title":"Mitragynine and 7-Hydroxymitragynine: Bidirectional effects on breathing in rats","volume":"392","author":"Zuarth Gonzalez","year":"2025","journal-title":"J. Pharmacol. Exp. Therapeut."}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027323002600245X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027323002600245X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:11:20Z","timestamp":1791501080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027323002600245X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":98,"alternative-id":["S027323002600245X"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106272","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond kratom: Concentrated 7-hydroxymitragynine and mitragynine pseudoindoxyl products, an MME potency assessment","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106272","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106272"}}